Monitor for official FDA meeting minutes and any updates on ABO-701 preclinical data. The 2027 IND timeline is unchanged and provides no near-term catalyst. Stock movement likely limited until concrete regulatory milestones are achieved.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $5.82entry
- T+1 · 6mo ago −6.19%α −3.59% · $5.46
- T+5 · 5mo ago −4.98%α −2.43% · $5.53
- T+20 · 4mo ago +9.97%α +11.34% · $6.40
- T+60 · 3mo ago +1.72%α −0.16% · $5.92
Price Chart
How similar events traded
Executive Summary
Abeona Therapeutics reported a constructive pre-IND meeting with the FDA regarding ABO-701, a novel T-cell therapy for prostate cancer. The company reaffirms its target to submit an IND application in 2027, but official FDA minutes are pending and no assurance of acceptance was given.
Key Facts
- Pre-IND meeting with FDA held on June 3, 2026 for ABO-701 (PSMA-targeted T-cell therapy for prostate cancer)
- Company believes meeting was constructive; official FDA minutes not yet received
- IND submission target remains 2027, consistent with prior timeline
- No financial figures, deal values, or clinical data disclosed in the filing
Financial Impact
No financial impact disclosed; pre-revenue clinical-stage company with no near-term revenue from ABO-701
Risk Factors
- FDA may require additional preclinical studies or data before accepting IND
- IND may not be accepted or may be delayed beyond 2027
- No assurance of clinical trial authorization or eventual approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027197 |
| Document: 0001493152-26-027197-index-headers.html | 0001493152-26-027197 |
| Document: 0001493152-26-027197-index.html | 0001493152-26-027197 |
| Document: 0001493152-26-027197.txt | 0001493152-26-027197 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers